During the the recent TechKnow roadshow in Sydney, LD touched on ARG007's multiple mechanisms of action which work across multiple conditions and says this in relation to its potential therapeutic use for Traumatic Brain Injury...
"The TBI data is starting to look really, really compelling. So again, there are no drugs, no therapeutic drugs on the market that can protect against brain injury in TBI. 69 million people globally suffer a TBI that warrants them going to a hospital every year. So you think the 5 billion dollar stroke market is big? The TBI therapeutic market is absolutely phenomenal."
AGN's presentation starts at about the 42 minute mark.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)